Skip to main content
. 2021 Sep 26;5:101. doi: 10.1186/s41687-021-00377-z

Table 3.

Sensitivity and specificity of the PRO-CTCAE items to probable sensory peripheral neuropathy and painful chemotherapy-induced peripheral neuropathy (CIPN)

Probable sensory peripheral neuropathy +
(n = 72)
Probable sensory peripheral neuropathy −
(n = 46)

Test + 

PRO-CTCAE Severity > 0/4

69 16

Test −

PRO-CTCAE Severity = 0/4

3 30
Sensitivity = 95.83% Specificity = 65.22%

Test +

PRO-CTCAE Interference > 0/4

37 12

Test −

PRO-CTCAE Interference = 0/4

35 34
Sensitivity = 51.39% Specificity = 73.91%
Painful CIPN + 
(n = 34)
Painful CIPN −
(n = 104)

Test +

PRO-CTCAE Severity > 0/4

34 64

Test −

PRO-CTCAE Severity = 0/4

0 40
Sensitivity = 100% Specificity = 38.46%

Test +

PRO-CTCAE Interference > 0/4

26 29

Test −

PRO-CTCAE Interference = 0/4

8 75
Sensitivity = 76.47% Specificity = 72.12%

Table describes the sensitivity and specificity of the PRO-CTCAE Numbness and Tingling Severity and Interference Items to probable sensory peripheral neuropathy (n = 118) or painful CIPN (n = 138) at T3. Participants who reported Total Neuropathy Score-Clinical Version (TNSc©) Sensory scores ≥ 1/4 and either TNSc© Sensory Function: Vibration Sensibility scores ≥ 1/4 or TNSc© Reflexes scores ≥ 1/4 were classified as exhibiting probable sensory peripheral neuropathy [38]. Participants who reported TNSc© Sensory scores = 0/4 were classified as not exhibiting probable sensory peripheral neuropathy. Participants who reported 0–10 numerical rating scale of worst CIPN pain intensity scores ≥ 4/10 over the past week were interpreted as indicating the presence of painful CIPN [39]. Participants who reported < 4/10 worst CIPN pain intensity over the past week were classified as not experiencing painful CIPN. Higher scores on all measures represented worse symptom severity